MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024.
Fourth Quarter Fiscal 2024 Summary
Fiscal Year 2024 Summary
Other Recent Operational Highlights
"Our team finished the year with a solid Q4 performance closing several opportunities that were open from the prior period. We secured new product approvals and significant customer wins, and initiated sales in new markets. These achievements and more have enabled us to establish a strong foundation from which to grow our global business in the years ahead," said Suzanne Winter, President and Chief Executive Officer. "As we look to fiscal 2025, we will continue to focus our investments on innovations driven by the voice of our customers. We remain confident in our ability to provide clinical teams worldwide with a product portfolio that enables them to elevate cancer care both today and into the future."
Fiscal Fourth Quarter Results
Total net revenue was $134.3 million for the fourth quarter of fiscal 2024, as compared to $118.3 million in the prior fiscal year fourth quarter. Product revenue totaled $79.7 million, as compared to $62.5 million in the prior fiscal year fourth quarter, while service revenue totaled $54.6 million, as compared to $55.8 million in the prior fiscal year fourth quarter.
Total gross profit in the fourth quarter of fiscal 2024 was $38.5 million, or 28.6 percent of net revenue, as compared to total gross profit of $37.7 million, or 31.9 percent of net revenue in the prior fiscal year fourth quarter.
Operating expenses were $31.6 million in the fourth quarter of fiscal 2024, as compared to $38.1 million in the prior fiscal year fourth quarter.
Net income was $3.4 million, or $0.03 per share, in the fourth quarter of fiscal 2024, as compared to a net loss of $2.6 million, or $0.03 per share, in the prior fiscal year fourth quarter. Adjusted EBITDA was $10.1 million in the fourth quarter of fiscal 2024 compared to $5.2 million in the prior fiscal year fourth quarter.
Gross orders totaled $95.5 million in the fourth quarter of fiscal 2024, as compared to $88.4 million in the prior fiscal year fourth quarter. Ending order backlog as of June 30, 2024 was $487.3 million, a decrease of 3.2 percent sequentially, and is 4.6 percent lower than at the end of the prior fiscal year fourth quarter.
Cash, cash equivalents, and short-term restricted cash were $69.1 million as of June 30, 2024, an increase of $7.9 million from March 31, 2024.
Fiscal Year 2024 Highlights
Total net revenue was $446.6 million for fiscal 2024, as compared to $447.6 million in the prior fiscal year period. Product revenue totaled $234.2 million, as compared to $233.2 million in the prior fiscal year period, while service revenue totaled $212.4 million, as compared to $214.4 million in the prior fiscal year period.
Total gross profit was $142.9 million for fiscal 2024, or 32.0 percent of net revenue, as compared to total gross profit of $154.0 million, or 34.4 percent of net revenue in the prior fiscal year period.
Operating expenses were $142.4 million for fiscal 2024, as compared to $151.6 million for the prior fiscal year period.
GAAP net loss was $15.5 million, or $0.16 per share, for the fiscal 2024, as compared to a net loss of $9.3 million, or $0.10 per share, in the prior fiscal year period. Adjusted EBITDA was $19.7 million for fiscal 2024, as compared to $23.9 million in the prior fiscal year period.
Gross orders totaled $342.1 million for fiscal 2024, as compared to $311.1 million in the prior fiscal year period.
Fiscal Year 2025 Financial Guidance
Accuray's financial guidance is based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market and economic conditions, supply chain disruption, and the factors set forth under "Safe Harbor Statement" below.
The Company is introducing guidance for fiscal year 2025 as follows:
"Our fourth quarter results reflect a concerted effort by our team to drive improvements in our financial performance while delivering world class products and services to our customers. Our operating results were solid with controlled expenses and strong management of working capital that resulted in a significant decline in inventory and increase in cash. Moving into fiscal 2025, I'm excited about the year ahead and the potential of our new products to help generate revenue and growth in service," said Ali Pervaiz, Chief Financial Officer.
Guidance for Adjusted EBITDA, a non-GAAP financial measures excludes depreciation and amortization, stock-based compensation expense, ERP and ERP related expenditures, interest expense and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the fourth quarter of fiscal 2024 as well as recent corporate developments. Conference call dial-in information is as follows:
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 3981744. An archived webcast will also be available on Accuray's website until Accuray announces its results for the first quarter of fiscal 2025.
Use of Non-GAAP Financial Measures
Accuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA and net revenue on a constant currency basis.
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, ERP and ERP related expenditures and restructuring charges ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. The GAAP measure most directly comparable to net revenue on a constant currency basis is revenue. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding: total revenue and adjusted EBITDA; the company's ability to invest on innovations and provide customers with products that enables them to elevate cancer care; the company's ability to benefit from advances in long-term growth and profitability drivers; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; the company's ability to deliver on its strategic growth plan, progressing against long-term strategic goals, and continuing adoption and expand access of its technologies; the company's ability to execute on margin and profitability expansion initiatives; expectations regarding commercial strategy and execution as well as growth opportunities; expectations regarding the company's China joint venture and the Tomo® C product as well as expectations with respect to other strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates and its ability to gain share in those markets and regions; expectations regarding new product introductions and innovations and their effect on use and adoption of the company's products; expectations regarding orders growth and its effect on market share as well as revenue, margin and adjusted EBITDA; expectations regarding backlog; expectations regarding the company's addressable market; expectations regarding service contract revenue; and the company's ability to advance patient care through innovation, expanded access to radiotherapy and improvements in overall profitability and working capital. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2024, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Aman Patel, CFA | Beth Kaplan |
Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
+1 (443) 450-4191 | +1 (408) 789-4426 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Financial Tables to Follow
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Net revenue: | ||||||||||||||||
Products | $ | 79,673 | $ | 62,454 | $ | 234,164 | $ | 233,192 | ||||||||
Services | 54,616 | 55,838 | 212,387 | 214,413 | ||||||||||||
Total net revenue | 134,289 | 118,292 | 446,551 | 447,605 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Cost of products | 55,084 | 42,000 | 161,061 | 153,627 | ||||||||||||
Cost of services | 40,753 | 38,614 | 142,569 | 140,018 | ||||||||||||
Total cost of revenue | 95,837 | 80,614 | 303,630 | 293,645 | ||||||||||||
Gross profit | 38,452 | 37,678 | 142,921 | 153,960 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 9,529 | 14,187 | 49,732 | 57,129 | ||||||||||||
Selling and marketing | 10,696 | 10,667 | 42,619 | 46,178 | ||||||||||||
General and administrative | 11,410 | 13,281 | 50,066 | 48,271 | ||||||||||||
Total operating expenses | 31,635 | 38,135 | 142,417 | 151,578 | ||||||||||||
Income (loss) from operations | 6,817 | (457) | 504 | 2,382 | ||||||||||||
Income on equity investment, net | 810 | 1,612 | 1,838 | 2,572 | ||||||||||||
Other expense, net | (3,769) | (3,131) | (14,162) | (11,742) | ||||||||||||
Income (loss) before provision for income taxes | 3,858 | (1,976) | (11,820) | (6,788) | ||||||||||||
Provision for income taxes | 471 | 580 | 3,725 | 2,492 | ||||||||||||
Net income (loss) | $ | 3,387 | $ | (2,556) | $ | (15,545) | $ | (9,280) | ||||||||
Net income (loss) per share - basic | $ | 0.03 | $ | (0.03) | $ | (0.16) | $ | (0.10) | ||||||||
Net income (loss) per share - diluted | $ | 0.03 | $ | (0.03) | $ | (0.16) | $ | (0.10) | ||||||||
Weighted average common shares used in computing income | ||||||||||||||||
Basic | 99,585 | 95,945 | 98,272 | 94,884 | ||||||||||||
Diluted | 101,028 | 95,945 | 98,272 | 94,884 | ||||||||||||
Accuray Incorporated | ||||||||
June 30, | June 30, | |||||||
2024 | 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 68,570 | $ | 89,402 | ||||
Restricted cash | 485 | 524 | ||||||
Accounts receivable, net | 92,001 | 74,777 | ||||||
Inventories | 138,324 | 145,150 | ||||||
Prepaid expenses and other current assets | 23,006 | 27,612 | ||||||
Deferred cost of revenue | 850 | 568 | ||||||
Total current assets | 323,236 | 338,033 | ||||||
Property and equipment, net | 24,774 | 20,926 | ||||||
Investment in joint venture | 9,826 | 15,128 | ||||||
Operating lease right-of-use assets | 33,773 | 25,853 | ||||||
Goodwill | 57,672 | 57,681 | ||||||
Intangible assets, net | 59 | 210 | ||||||
Restricted cash | 1,337 | 1,276 | ||||||
Other assets | 17,950 | 20,107 | ||||||
Total assets | $ | 468,627 | $ | 479,214 | ||||
Liabilities and equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 50,020 | $ | 33,739 | ||||
Accrued compensation | 17,128 | 23,793 | ||||||
Operating lease liabilities, current | 6,218 | 4,151 | ||||||
Other accrued liabilities | 28,508 | 38,271 | ||||||
Customer advances | 13,988 | 20,777 | ||||||
Deferred revenue | 71,649 | 72,185 | ||||||
Short-term debt | 7,756 | 5,721 | ||||||
Total current liabilities | 195,267 | 198,637 | ||||||
Operating lease liabilities, non-current | 32,373 | 23,602 | ||||||
Long-term other liabilities | 7,389 | 4,675 | ||||||
Deferred revenue | 24,114 | 27,079 | ||||||
Long-term debt | 164,400 | 171,562 | ||||||
Total liabilities | 423,543 | 425,555 | ||||||
Equity: | ||||||||
Common stock | 100 | 97 | ||||||
Additional paid-in capital | 566,887 | 555,276 | ||||||
Accumulated other comprehensive income (loss) | (4,222) | 422 | ||||||
Accumulated deficit | (517,681) | (502,136) | ||||||
Total equity | 45,084 | 53,659 | ||||||
Total liabilities and equity | $ | 468,627 | $ | 479,214 | ||||
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Gross Orders | $ | 95,472 | $ | 88,447 | $ | 342,148 | $ | 311,094 | ||||||||
Net Orders | 63,773 | 67,756 | 210,914 | 182,932 | ||||||||||||
Order Backlog | 487,319 | 510,641 | 487,319 | 510,641 | ||||||||||||
Book to bill ratio (a) | 1.2 | 1.4 | 1.5 | 1.3 | ||||||||||||
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period |
Accuray Incorporated | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
GAAP net income (loss) | $ | 3,387 | $ | (2,556) | $ | (15,545) | $ | (9,280) | ||||||||
Depreciation and amortization (a) | 1,507 | 1,097 | 5,905 | 4,527 | ||||||||||||
Stock-based compensation | 2,042 | 2,452 | 9,483 | 10,053 | ||||||||||||
Interest expense, net (b) | 2,686 | 2,735 | 10,676 | 10,340 | ||||||||||||
Provision for income taxes | 471 | 580 | 3,725 | 2,492 | ||||||||||||
Restructuring charges | — | — | 2,633 | 2,738 | ||||||||||||
ERP and ERP related expenditures | — | 900 | 2,815 | 3,078 | ||||||||||||
Adjusted EBITDA | $ | 10,093 | $ | 5,208 | $ | 19,692 | $ | 23,948 | ||||||||
(a) Consists of depreciation, primarily on property and equipment, as well as amortization of intangibles. |
(b) Consists primarily of interest expense associated with outstanding debt. |
Accuray Incorporated | ||||||||
Twelve Months Ending | ||||||||
From | To | |||||||
GAAP net loss | $ | (5,000) | $ | (3,000) | ||||
Depreciation and amortization (a) | 6,500 | 6,500 | ||||||
Stock-based compensation | 10,000 | 10,000 | ||||||
Interest expense, net (b) | 13,000 | 13,000 | ||||||
Provision for income taxes | 3,000 | 3,000 | ||||||
Adjusted EBITDA | $ | 27,500 | $ | 29,500 | ||||
(a) Consists of depreciation, primarily on property and equipment as well, as amortization of intangibles. |
(b) Consists primarily of interest expense associated with outstanding debt. |
| Last Trade: | US$1.85 |
| Daily Change: | 0.06 3.35 |
| Daily Volume: | 655,700 |
| Market Cap: | US$186.040M |
November 06, 2024 September 10, 2024 August 27, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
